Intellectual Property India Publishes Patent Application for 'Antibody-Drug Conjugate, Preparation Method Therefor And Use Thereof In Resisting Tumors' Filed by Multitude Therapeutics Inc.

MUMBAI, India, June 6 -- Intellectual Property India has published a patent application (202517047431 A) filed by Multitude Therapeutics Inc., Shanghai, on May 16, for 'antibody-drug conjugate, preparation method therefor and use thereof in resisting tumors.'

Inventor(s) include Meng, Xun; and Weng, Weining.

The application for the patent was published on June 6, under issue no. 23/2025.

According to the abstract released by the Intellectual Property India: "An antibody-drug conjugate, a preparation method therefor and the use thereof in resisting tumors, which specifically relates to an anti-HER3 antibody or an antigen-binding fragment thereof, and an antibody-drug conjugate linked to the antibody. The antibody-drug conjugate has a structure as shown in Ab-(L-D)n, and is covalently linked with an effective load with cytotoxicity via a linker. The anti-HER3 antibody or the antigen-binding fragment thereof and the antibody-drug conjugate have a use in the preparation of a therapeutic agent for diagnosing, preventing and treating tumor diseases."

The patent application was internationally filed on Oct. 18, 2023, under International application No.PCT/CN2023/125269.

Disclaimer: Curated by HT Syndication.